Diseases of the Esophagus

Papers
(The median citation count of Diseases of the Esophagus is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
147. CHARACTERISTICS AND PREDICTORS OF EARLY POSTOPERATIVE RECURRENCE OF ESOPHAGEAL CANCER37
021. THE TOTALLY MECHANICAL COLLARD TECHNIQUE FOR CERVICAL ESOPHAGOGASTRIC ANASTOMOSIS REDUCES ANASTOMOTIC STRICTURE COMPARED WITH TRIANGULAR ANASTOMOSIS: A PROPENSITY SCORE-MATCHED STUDY30
159. AUDIT OF POSTOPERATIVE COMPLICATIONS ACCORDING TO PATHOLOGICAL RESPONSE AFTER TRIMODALITY THERAPY IN OESOPHAGEAL CANCER29
118. USEFULNESS OF PERIOPERATIVE NUTRITIONAL THERAPY WITH THE GLUTAMINE/ARGININE/CALCIUM β-HYDROXY-β-METHYLBUTYRATE PRODUCT IN ESOPHAGEAL CANCER SURGERY27
180. PROGNOSTIC INFLUENCE OF POSTOPERATIVE CRP LEVELS AFTER THORACOSCOPIC ESOPHAGECTOMY IN PATIENTS WITH ESCC25
167. A CASE REPORT: PERFORATION OF THE ESOPHAGUS CAUSED BY CHOPSTICKS21
047. ASSOCIATION OF DIETARY FACTORS AND VOLATILE ORGANIC COMPOUNDS IN STOOL SAMPLES IN PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE21
237. IMPACT OF LYMPH NODE DISSECTION ON PROGNOSIS IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA PATIENTS UNDERGOING NEOADJUVANT CHEMOIMMUNOTHERAPY FOLLOWED BY RADICAL SURGERY21
033. PERIOPERATIVE OUTCOMES OF ROBOT-ASSISTED ESOPHAGECTOMY: A 15-YEAR COMPARATIVE ANALYSIS OF 1401 CASES WITH OPEN AND VATS20
156. COMPARISON OF SHORT-TERM POSTOPERATIVE OUTCOMES BETWEEN HAND-ASSISTED LAPAROSCOPIC SURGERY AND LAPAROSCOPIC SURGERY FOR ABDOMINAL APPROACHES IN ESOPHAGEAL CANCER SURGERY20
107. CAMRELIZUMAB AND LOW-DOSE RADIOTHERAPY WITH CONCURRENT CHEMORADIOTHERAPY FOR LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA (NICE-RT STUDY): PRELIMINARY RESULTS19
297. COMPARING SURVIVAL AND COMPLICATION RATES IN CERVICAL VS. INTRATHORACIC ANASTOMOSIS FOR ELDERLY ESOPHAGEAL CANCER PATIENTS19
287. CAMRELIZUMAB, PACLITAXEL AND NEDAPLATIN AS NEOADJUVANT THERAPY FOR LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESPRIT): A PHASE II, SINGLE-ARM STUDY18
092. COPING MECHANISMS FOR FINANCIAL TOXICITY AND ITS ASSOCIATION WITH HEALTH-RELATED QUALITY OF LIFE IN ESOPHAGEAL CANCER SURVIVORS17
Can FLIP guide therapy in idiopathic esophagogastric junction outflow obstruction?15
The broad impact of functional lumen imaging probe panometry in addition to high-resolution manometry in an esophageal clinical practice15
280. FEASIBILITY OF ROBOTIC-ASSISTED SURGERY FOR BENIGN ESOPHAGEAL LESIONS: SINGLE-CENTER EXPERIENCE14
321. ESD AND ELPS A NOVEL MINIMALLY INVASIVE TREATMENT FOR MULTI-EPISODE SUPERFICIAL ESOPHAGEAL SCC AND 2ND PRIMARY HYPOPHARYNGEAL SCC:A CASE REPORT13
538. A DECADE OF ESOPHAGEAL AND ESOPHAGO-GASTRIC JUNCTION CANCER EPIDEMIOLOGY IN NATIONAL CANCER INSTITUTE MEXICO13
523. RISK FACTORS ASSOCIATED WITH NOT RECEIVING ADJUVANT CHEMOTHERAPY FOR LOCALLY ADVANCED ESOPHAGOGASTRIC ADENOCARCINOMA12
539. SURGICAL TECHNIQUES AND OUTCOMES OF GASTRIC CONDUIT RECONSTRUCTION FOLLOWING ESOPHAGECTOMY BY HAND-ASSISTED LAPAROSCOPIC SURGERY (HALS) FOR ESOPHAGEAL CANCER12
Modified reconstruction procedure in subtotal esophagectomy with retrosternal gastric pull up to reduce anastomotic leakage: a propensity score-matched analysis12
294. LEARNING CURVE OF MINIMALLY INVASIVE ESOPHAGECTOMY: OUR SERIES, SYSTEMATIC REVIEW OF THE LITERATURE AND META-ANALYSIS11
173. FEASIBILITY AND POTENTIAL ADVANTAGE OF ROBOT-ASSISTED ESOPHAGECTOMY FOR CT4B ESOPHAGEAL CANCER11
226. PHILOSOPHICAL CONSIDERATIONS IN SURGICAL INNOVATION11
158. PACLITAXEL PLUS CISPLATIN AND 5 FUOROURACIL INDUCTION CHEMOTHERAPY FOR BORDERLINE RESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA: 3-YEAR SURVIVAL RESULT11
Pressure dynamics of the esophagogastric junction at rest and during inspiratory maneuvers after Nissen fundoplication11
245. CLINICAL UTILITY OF CTDNA IN LONGITUDINAL MONITORING OF TREATMENT RESPONSES AND RELAPSE IN METASTATIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA11
266. EXTENSION OF FDG-PET-BASED RADIOMIC MODELS ON IDENTIFICATION OF PATIENTS WITH RESIDUAL ESOPHAGEAL CANCER AFTER NEOADJUVANT CHEMORADIOTHERAPY10
Diagnostic differences in high-resolution esophageal motility in a large Mexican cohort based on geographic distribution10
643. PRACTICAL IMAGING REVIEW OF EXPECTED FINDINGS AND POSSIBLE COMPLICATIONS RELATED TO MULTIMODAL TREATMENT OF ESOPHAGEAL CANCER10
29: INCIDENCE, DIAGNOSIS AND MANAGEMENT OF MALABSORPTION FOLLOWING OESOPHAGECTOMY: A SYSTEMATIC REVIEW10
327. ANALYSING THE ROLE OF PET-CT IN ESOPHAGEAL CANCER: A SINGLE CENTRE COHORT STUDY10
Novel histologic score predicts recurrent intestinal metaplasia after successful endoscopic eradication therapy10
570. ADRENAL METASTASES OF ESOPHAGEAL CANCER: SURGICAL MANAGEMENT OF SINGLE METASTASES10
Validation of the Swedish Watson Dysphagia Scale for adult patients with eosinophilic esophagitis9
765. PATTERNS, TIMING, AND SURVIVAL OF RECURRENCE FOLLOWING SURGERY FOR ESOPHAGEAL ADENOCARCINOMA IN THE EUROPEAN MULTICENTRE ENSURE STUDY9
Correction to: Radial incision and cutting for dilation before endoscopic submucosal dissection in patients with esophageal cancer on the distal side of severe benign esophageal strictures9
793. MODIFIED HELLER DOR FOR ACHALASIA9
239. EVALUATION OF SUBCARINAL LYMPH NODE DISSECTION AND METASTASIS IN TRANSMEDIASTINAL RADICAL ESOPHAGECTOMY9
594. TOTALLY MINIMALLY INVASIVE 2-STAGE ESOPHAGECTOMY VERSUS HYBRID 2-STAGE ESOPHAGECTOMY. A SINGLE CENTER EXPERIENCE9
408. COMPARISON OF THE SHORT-TERM EFFICACY OF THORACOSCOPY COMBINED WITH GASTROSCOPY AND TRADITIONAL THORACOTOMY IN THE TREATMENT OF SPONTANEOUS ESOPHAGEAL RUPTURE9
411. SINGLE-PORT THORACOSCOPIC RESECTION FOR THE SPINDLE CELL TUMOR OF ESOPHAGUS9
269. PATIENT-DERIVED TUMOR ORGANOIDS AND XENOGRAFTS AS BASIC AND PRECLINICAL TRANSLATIONAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MODELS9
803. 2-YEAR RESULTS IN ESOPHAGOGASTRIC JUNCTION CANCER TREATMENT9
535. AUDITING THE PATIENTS OUTCOMES AFTER SURGERY FOR ESOPHAGEAL AND GASTRIC CARDIA CANCER WITHIN THE 18 YEARS PERIOD. SINGLE CENTER EXPERIENCE8
739. SIGNIFICANCE OF COX2 INHIBITOR FOR ESOPHAGEAL CANCER FROM THE CLINICAL AND EXPERIMENTAL ESTIMATE8
44. LONG-TERM OUTCOMES OF PERORAL ENDOSCOPIC MYOTOMY FOR PATIENTS WITH ACHALASIA: A SINGLE-CENTRE STUDY8
461. SURGICAL TREATMENT OF STAGE IV ESOPHAGEAL CANCER AFTER CCRT IMPROVES SURVIVAL8
770. CLOSURE OF OESOPHAGEAL DEFECTS USING THE VACSTENT DEVICE: INITIAL INSIGHTS FROM THE LARGEST UK CASE SERIES8
369. GENOMIC ALTERATIONS AND SURVIVAL AFTER TREATMENT OF EAC BY SURGERY WITHOUT CHEMO- OR RADIOTHERAPY8
The interventional esophagologist: tunneling a new way forward8
487. THE OUTCOME OF NIVOLUMAB THERAPY FOR PLATINUM-RESISTANT UNRESECTABLE ADVANCED OR RECURRENT ESOPHAGEAL CANCER8
189. IDENTIFICATION OF M6A-RELATED SIGNATURE GENES IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA BY MACHINE LEARNING METHOD7
466. ROBOT-ASSISTED CERVICAL ESOPHAGECTOMY (RACE) FOR ESOPHAGEAL CANCER: THE FIRST TWO CASES OF AN ITALIAN HIGH-VOLUME CENTER7
Disruption of the brain–esophagus axis in obese patients with heartburn7
489. EVALUATION OF THE ONCOLOGICAL QUALITY OF MINIMALLY INVASIVE TRANSCERVICAL OESOPHAGECTOMY (MICE) USING A CADAVERIC MODEL7
378. LAPAROSCOPIC PRIMARY CLOSURE OF ESOPHAGEAL RUPTURE CAUSED BY BALLOON DILATATION FOR ACHALASIA AND HELLER'S MYOTOMY WITH DOR FUNDOPLICATION7
259. ROBOTIC ESOPHAGECTOMY AND THREE FIELD LYMPHADENECTOMY WITH INTRA-OPERATIVE RECURRENT LARYNGEAL NERVE MONITORING7
207. THE EVOLUTION OF THE PERIOPERATIVE ENHANCED RECOVERY PROTOCOL IN ESOPHAGEAL SURGERY DURING 10 YEARS7
252. RIGHT GASTROEPIPLOIC ARTERY LENGTH DETERMINED ANASTOMOTIC LEAKRIGHT GASTROEPIPLOIC ARTERY LENGTH DETERMINED ANASTOMOTIC LEAKAGE AFTER MINIMALLY INVASIVE ESOPHAGECTOMY FOR ESOPHAGEAL CANCER-A PROS7
In vitro and in vivo evaluation of a novel wired transmission pH-combined photographic catheter for ambulatory gastroesophageal reflux monitoring (with videos)7
326. SPONTANEOUS OESOPHAGEAL PERFORATION TREATED WITH OESOPHAGEAL STENT7
34. EXTENDED RIGHT THORACIC APPROACH COMPARED WITH LIMITED LEFT THORACIC APPROACH FOR ESOPHAGEAL CANCER: TEN-YEAR SURVIVAL OF A PROSPECTIVE RANDOMIZED TRIAL7
255. EARLY COST-EFFECTIVENESS MODELLING STUDY COMPARING MINIMALLY INVASIVE TRANSCERVICAL ESOPHAGECTOMY (MICE) AND TRANSTHORACIC MINIMALLY INVASIVE ESOPHAGECTOMY (TMIE) IN OESOPHAGEAL CANCER PATIENTS7
498. LATROGENIC ESOPHAGEAL DISEASE POST OBESITY TREATMENT: SEVERE ESOPHAGEAL DILATATION RELATED TO ADJUSTABLE GASTRIC BANDING (AGB)7
478. ENDOSCOPIC RESECTION OF A HUGE ESOPHAGEAL LIPOSARCOMA WITH LIGASURE INSTRUMENT7
Characteristics analyses and tumor staging proposal for primary malignant melanoma of the esophagus: a retrospective study7
611. THE UTILITY OF H ANASTOMOSIS IN INFLATABLE MEDIASTINOSCOPE-ASSISTED TRANSHIATAL ESOPHAGECTOMY FOR ESOPHAGEAL CANCER7
Ki-67 overexpression for risk stratification of early dysplasia in Barrett’s esophagus: Friend or foe?7
Omission of intraoperative pyloric procedures in minimally invasive esophagectomy: assessing the impact on patients6
600. DETECTION OF ANASTOMOTIC LEAK THROUGH THE VALUE OF DRAIN FLUID AMYLASE6
209: ROLE OF ADJUVANT CHEMOTHERAPY IN LOW BURDEN (YPT0-T1N0) GASTRIC ADENOCARCINOMA AFTER NEOADJUVANT CHEMOTHERAPY6
632. CAN CARDIOPULMONARY EXERCISE TESTING PREDICT NEOADJUVANT CHEMOTHERAPY TOXICITY IN OESOPHAGEAL ADENOCARCINOMA PATIENTS?6
457. EVALUATING THE ACCURACY OF CLINICAL SIEWERT CLASSIFICATION, A RETROSPECTIVE REVIEW OF 807 PATIENTS6
599. ASSESSMENT OF BREATHING MECHANICS IN OESOPHAGEAL CANCER SURVIVORS USING A 3D-MOTION CAPTURE SYSTEM6
178. OUTCOME OF DOCETAXEL, CISPLATIN, AND 5-FLUOROURACIL COMBINATION CHEMORADIOTHERAPY FOR LOCALLY ADVANCED ESOPHAGEAL CANCER6
777. COMBINED OESOPHAGEAL AND AIRWAY STENTING FOR MALIGNANT OESOPHAGEAL STRICTURES: THE UK’S LARGEST TERTIARY CENTRE EXPERIENCE AND DEVELOPMENT OF A NOVEL ALGORITHM6
605. NEOADJUVANT FLOT FOR LOCALLY ADVANCED ESOPHAGEAL CANCERS: A SYSTEMATIC REVIEW AND META-ANALYSIS6
278. SHORT- AND LONG-TERM OUTCOME AFTER UPFRONT SURGERY OR NEOADJUVANT CHEMOTHERAPY FOLLOWED BY SURGERY IN ELDERLY PATIENTS WITH RESECTABLE ESOPHAGEAL CANCER6
Feeding gastrostomy and duodenostomy using the round ligament of the liver versus conventional feeding jejunostomy after esophagectomy: a meta-analysis6
421. UNVEILING THE COMPLEXITY—DISSECTION OF 106 LYMPH NODES IN ESOPHAGEAL CANCER6
273. PERIOPERATIVE BLOOD TRANSFUSIONS AND SURVIVAL IN GASTROESOPHAGEAL CANCERS – A SWEDISH POPULATION-BASED STUDY6
247. BASELINE 18F-FDG PET/CT SUVMAX AS A PROGNOSTIC INDICATOR FOR LONG-TERM SURVIVAL IN POSTOPERATIVE ESOPHAGEAL SQUAMOUS CELL CARCINOMA5
Magnetic sphincter augmentation and high-resolution manometry: impact of biomechanical properties on esophageal motility and clinical significance for selection and outcomes5
619. THE STRATEGY OF THE SURGICAL TREATMENT FOR ESOPHAGEAL NEUROENDOCRINE CARCINOMA5
472. ROUTINE PLACEMENT OF FEEDING TUBES SHOULD BE AVOIDED IN ESOPHAGEAL CANCER PATIENTS UNDERGOING SURGERY5
307. INGENUITY OF ESOPHAGOGASTRIC ANASTOMOSIS IN OUR DEPARTMENT -RECONSTRUCTED GASTRIC TUBE STUMP CLOSURE USING ENDO GIA RADIAL RELOAD5
417. ROBOT-ASSISTED MINIMALLY INVASIVE ESOPHAGECTOMY WITH UPPER MEDIASTINAL LYMPHADENECTOMY5
260. RECURRENT EROSIVE ESOPHAGITIS AFTER SURGICAL TREATMENT IN DIFFERENT TYPE OF ACHALASIA5
406. EXPLORING THE OPTIMAL TIMING OF MINIMALLY INVASIVE SURGERY FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA AFTER NEOADJUVANT CHEMORADIOTHERAPY5
Performance of radiomics-based artificial intelligence systems in the diagnosis and prediction of treatment response and survival in esophageal cancer: a systematic review and meta-analysis of diagnos5
502. CORRELATION OF LYMPH NODE SIZE WITH METASTATIC INVOLVEMENT IN PATIENTS WITH OESOPHAGEAL CANCER5
372. ASSESSMENT OF TUMOR REGRESSION GRADE IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA AFTER CHEMORADIOTHERAPY: COMPARISON OF 3 COMMONLY USED SCORING SYSTEMS5
How much progress have we made?: a 20-year experience regarding esophageal stents for the palliation of malignant dysphagia5
330. RIGHT DIAPHRAGMATIC HERNIA FOLLOWING PARA OESOPHAGEAL HERNIA REPAIR5
420. MESH REINFORCEMENT IN HIATAL HERNIA REPAIR: CLINICAL RESULTS OF OUR EARLY EXPERIENCE5
516. MICRONUTRIENT DEFICIENCIES AFTER GASTROESOPHAGEAL CANCER SURGERY5
795. REVIEW OF CLINICAL CHARACTERISTICS AND PROGNOSIS OF MULTIPLE PRIMARY ESOPHAGEAL SQUAMOUS CELL CARCINOMA5
What is the significance of the Hill classification?5
222. ARE GASTRIC MAPPING BIOPSIES NECESSARY TO DETERMINE THE DISTAL RESECTION MARGIN FOR SIGNET RING ADENOCARCINOMAS OF THE OESOPHAGO-GASTRIC JUNCTION?4
441. COMBINING LARYNGEAL ULTRASONOGRAPHY (LUSG) WITH VOICE ASSESSMENT OR INTRA-OPERATIVE NERVE MONITORING RESULTS ACCURATELY CONFIRMS NORMAL VOCAL CORD FUNCTION AFTER ESOPHAGECTOMY4
383. LOSS OF PERISTALTIC RESERVE DETERMINED BY MULTIPLE RAPID SWALLOWS CORRELATES WITH DYSPHAGIA AND POOR BOLUS TRANSIT IN INEFFECTIVE ESOPHAGEAL MOTILITY4
Laparoscopic total fundoplication is superior to medical treatment for reducing the cancer risk in Barrett’s esophagus: a long-term analysis4
Neoadjuvant versus definitive chemoradiation in locally advanced esophageal cancer for patients of advanced age or significant comorbidities4
463. PREOPERATIVE ASSESSMENT USING A SCORING SYSTEM AFTER NEOADJUVANT CHEMOTHERAPY WITH DOCETAXEL, CISPLATIN AND 5-FLUOROURACIL FOR LOCALLY ADVANCED ESOPHAGEAL CANCER4
Management and outcomes in a consecutive series of patients with aero-digestive fistula at a tertiary gastro-esophageal surgery center4
104. RISK FACTORS FOR ANASTOMOTIC LEAKAGE AFTER ESOPHAGEAL SUBTOTAL RESECTION AND GASTRIC TUBE RECONSTRUCTION U USING ICG FLUORESCENCE4
256. PROGNOSIS AND RISK FACTORS FOR SUPRACLAVICULAR LYMPH NODE METASTASIS IN PATIENTS WITH MIDDLE AND LOWER THORACIC ESOPHAGEAL CANCER4
557. POTENTIAL THERAPEUTIC TARGETS OF TRPV2 AND SLC12A2 IN ESOPHAGEAL ADENOCARCINOMA CANCER STEM CELLS4
478. OVERVIEW ON USE OF THE TRANSCERVICAL MEDIASTINOSCOPIC APPROACH FOR MINIMALLY INVASIVE TREATMENT OF ESOPHAGEAL CANCER: ESTABLISHMENT OF INTERNATIONAL COLLABORATIVE GROUP4
427. CAN WE OPTIMIZE THE RECOMMENDATIONS FOR FOLLOW-UP OF BARRETT’S ESOPHAGUS THROUGH CRITICAL ANALYSIS OF RISK FACTORS IN A SPECIFIC POPULATION?4
Research gap in esophageal achalasia: a narrative review4
228. THORACOACROMIAL ARTERY PERFORATOR FLAP REPAIR OF ACQUIRED INTRATHORACIC NONMALIGNANT TRACHEOESOPHAGEAL FISTULAS THROUGH A MIDSTERNAL INCISION APPROACH4
210. DEVELOPMENT OF NOVEL IMMUNOTHERAPY-BASED THERAPIES IN OESOPHAGEAL ADENOCARCINOMA BY HARNESSING TUMOUR NEOANTIGENS4
172. STRATEGY OF SALVAGE ESOPHAGECTOMY AFTER DEFINITIVE CHEMORADIOTHERAPY FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA4
457. A CASE OF ADVANCED ESOPHAGEAL CANCER WITH SITUS INVERSUS TOTALIS SUCCESSFULLY TREATED WITH THORACOSCOPIC SUBTOTAL ESOPHAGECTOMY4
213. A NEW MANOMETRIC TOOL TO EVALUATE THE EFFICACY OF LAPAROSCOPIC ANTIREFLUX SURGERY4
380. INTEGRATIVE TRANSCRIPTOMIC AND FUNCTIONAL ANALYSIS OF CHEMOTHERAPY RESISTANCE IN ESOPHAGEAL ADENOCARCINOMA4
556. PREDICTORS OF EARLY RECURRENCE AFTER OESOPHAGECTOMY AND NEOADJUVANT FLOT4
Safety, efficacy, and cost-effectiveness of minimally invasive esophagectomies versus open esophagectomies: an umbrella review4
534. EVALUATION OF SURGICAL OUTCOMES IN ROBOTIC-ASSISTED ESOPHAGECTOMY4
451. PREDICTIVE FACTORS FOR PNEUMONIA AND ANASTOMOTIC LEAK AFTER TRANSTHORACIC ESOPHAGECTOMY FOR CANCER AND FAILURE TO RESCUE ANALYSIS ON 1355 PATIENTS4
Gastroesophageal reflux disease following laparoscopic vertical sleeve gastrectomy and laparoscopic roux-en-Y gastric bypass: meta-analysis and systematic review of 5-year data4
030. PROGNOSTIC SIGNIFICANCE OF LOW HER2 EXPRESSION IN ADENOCARCINOMA OF THE ESOPHAGOGASTRIC JUNCTION: A RETROSPECTIVE ANALYSIS4
101. INITIAL EXPERIENCE WITH UNDERWATER PERORAL ENDOSCOPIC MYOTOMY (U-POEM) IN THE TREATMENT OF ACHALASIA AT TAM ANH HOSPITAL, HO CHI MINH4
446. EFFECT OF PANCREATIC JUICE AND BILE REFLUX TO THE DEVELOPMENT OF ESOPHAGEAL CARCINOGENESIS IN RAT MODEL4
269. LARGE CELL NEUROENDOCRINE CARCINOMA OF THE OESOPHAGUS: A RARE ENTITY. SYSTEMATIC REVIEW OF THE LITERATURE IN REGARDS TO ITS MANAGEMENT4
342. GENOMIC ANALYSIS OF RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN OESOPHAGEAL ADENOCARCINOMA4
515. EXOCRINE PANCREATIC FUNCTION IN PATIENTS AFTER ESOPHAGECTOMY; IS TREATMENT WITH PANCREATIC ENZYMES NECESSARY?3
252. ACCURACY OF PREDICTING RESIDUAL DISEASE AND DISEASE PROGRESSION DURING ACTIVE SURVEILLANCE FOR ESOPHAGEAL CANCER3
177. BULKY LYMPHADENOPATHY IN ESOPHAGEAL CANCER: ASSESSING PATHOLOGICAL AND SURVIVAL OUTCOMES AFTER TREATMENT WITH CURATIVE INTENT3
317. WHAT IS THE APPROPRIATE TREATMENT STRATEGY FOR SUPERFICIAL ESOPHAGEAL CANCER WITH SYNCHRONIZED HEAD AND NECK CANCER?3
243. IS MUCOSAL CHANGE IN COELIAC DISEASE RESTRICTED TO SMALL BOWEL? STUDY OF OESOPHAGEAL MUCOSAL CHANGES IN CHILDREN WITH COELIAC DISEASE3
328. DEVELOPMENT OF A MACHINE LEARNING-BASED PROGRAMMED CELL DEATH GENES PROGNOSTIC MODEL FOR ESOPHAGEAL CARCINOMA3
333. TECHNICAL CONSIDERATIONS IN UPPER-GI RECONSTRUCTION – A CASE SERIES3
241. EVALUATION OF THE PYLORUS FOLLOWING GASTRIC CONDUIT RECONSTRUCTION IN OESOPHAGECTOMY USING IMPEDANCE PLANIMETRY—A SYSTEMATIC REVIEW WITH META-ANALYSIS3
549. LAPAROSCOPIC CARDIOPLASTY FOR FAILED PRIMARY TREATMENT OF ACHALASIA3
439. ACUTE GASTRIC VOLVULUS—LATE OCCURRENCE AFTER HIATAL HERNIA REPAIR WITH MESH3
303. A NOVEL ‘WATERFALL METHOD’ OF FILLING THE POSTERIOR MEDIASTINAL CAVITY AFTER ESOPHAGECTOMY USING OMENTAL FLAP IN RETROSTERNAL GASTRIC TUBE RECONSTRUCTION3
184. INTRATHORACIC SIDE-OVERLAP ESOPHAGOGASTROSTOMY DURING MINIMALLY INVASIVE ESOPHAGECTOMY FOR ESOPHAGOGASTRIC JUNCTION CANCER3
Comparing clinical outcomes of peroral endoscopic myotomy for achalasia between Eastern and Western countries: a systematic review and meta-analysis3
Is proton-pump inhibitor effective in preventing postoperative bleeding after esophageal endoscopic submucosal dissection?3
260. EFFECT OF ENDOLUMINAL VACUUM THERAPY ON THE PERFUSION OF GASTRIC CONDUIT IN A PORCINE MODEL FOR ESOPHAGECTOMY3
305. GASTROESOPHAGEAL REFLUX DISEASE IN LUNG TRANSPLANT RECIPIENTS IN ASIA3
604. REAL-WORLD MANAGEMENT AND OUTCOMES OF PATIENTS WITH NON METASTATIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA IN THE FREGAT DATABASE3
410. THE RELATIONSHIP BETWEEN GASTRIC CONDUIT EMPTYING, FUNCTIONAL ANATOMY AND PERISTALSIS: A DETAILED ANALYSIS USING DYNAMIC MAGNETIC RESONANCE IMAGING3
143. NEOADJUVANT CHEMORADIOTHERAPY VERSUS CHEMOTHERAPY FOR THE TREATMENT OF LOCALLY ADVANCED ESOPHAGEAL ADENOCARCINOMA IN THE EUROPEAN MULTICENTER ENSURE STUDY3
262. THE NUMBER OF CAJAL CELLS IN MUSCLE LAYER OF THE ESOPHAGUS IN PATIENTS WITH ACHALASIA3
496. OESOPHAGEAL STENTING IN BOERHAAVE SYNDROME: OUR EXPERIENCE3
Sex- and gender-specific differences in symptoms and health-related quality of life among patients with gastroesophageal reflux disease3
600. TREATMENT OUTCOME OF CLINICALLY UNRESECTABLE ESOPHAGEAL CANCER AFTER NEO-ADJUVANT CHEMOTHERAPY WITH DOCETAXEL, CISPLATIN AND 5-FLUOROURACIL3
236. INDOCYANINE GREEN TRACHEOBRONCHIAL FLUORESCENCE (ICG-TBF) VIA NEBULIZATION DURING MINIMALLY INVASIVE ESOPHAGECTOMY -A NOVEL TECHNIQUE3
754. PATHOLOGICAL RESPONSE PREDICTS EFFICACY OF ADJUVANT FLOT CHEMOTHERAPY IN GASTROESOPHAGEAL CANCER: AN INTERNATIONAL COHORT STUDY3
272. IMPLEMENTATION OF AN ERAS PROTOCOL IN PATIENTS UNDERGOING ESOPHAGECTOMY: EVALUATION OF THE RESULTS3
A systematic review of hiatus hernia classifications3
Management of esophageal anastomotic leaks, a systematic review and network meta-analysis3
Clinical frailty is a risk factor of adverse outcomes in patients with esophageal cancer undergoing esophagectomy: analysis of 2011–2017 US hospitals3
265. THE COST-EFFECTIVENESS OF RISK-BASED MANAGEMENT OF BARRETT’S ESOPHAGUS PATIENTS USING TISSUECYPHER OR P53 BIOMARKERS: A MICROSIMULATION STUDY3
549. CLINICAL IMPLICATIONS OF SELECTIVE RIGHT PARATRACHEAL LYMPH NODE DISSECTION IN PATIENTS WITH EARLY-STAGE ESOPHAGEAL CANCER: PROPENSITY-SCORE MATCHED ANAYLSIS3
143. LONG-TERM DYSPHAGIA AND REGURGITATION IN 10-YEAR ESOPHAGEAL SQUAMOUS CELL CARCINOMA SURVIVORS: PREVALENCE, CORRELATES, AND PREDICTIVE MODELS IN A MULTI-CENTER COHORT3
148: LAPAROSCOPIC FUNDOPLICATION FOR PARA-ESOPHAGEAL HERNIA REPAIR IMPROVES RESPIRATORY FUNCTION IN PATIENTS PRESENTING WITH DYSPNEA: A PROSPECTIVE COHORT STUDY3
023. CHEMOTHERAPY COMBINED WITH IMMUNOTHERAPY FOLLOWED BY SALVAGE LYMPHADENECTOMY FOR RECURRENCE IN CERVICAL LYMPH NODES AFTER ESOPHAGECTOMY: A SINGLE-CENTER PROSPECTIVE STUDY3
303. THE TISSUE SYSTEMS PATHOLOGY-9 TEST PROVIDES CLINICALLY-IMPACTFUL RISK STRATIFICATION IN PATIENTS WITH BARRETT’S ESOPHAGUS: CLINICAL EXPERIENCE IN A MULTICENTER COHORT3
010. UTILITY OF ROBOTIC-ASSISTED ESOPHAGECTOMY FOR ESOPHAGEAL CANCER BASED ON LONG-TERM SURVIVAL: A PROPENSITY SCORE ANALYSIS COMPARED WITH THORACOSCOPIC SURGERY3
406. A SYSTEMATIC REVIEW AND META-ANALYSIS ON THE USE OF ARTIFICIAL INTELLIGENCE IN THE ENDOSCOPIC DIAGNOSIS OF ESOPHAGEAL CANCER3
326. REDUCTION OF ANASTOMOTIC LEAKAGE AFTER ESOPHAGECTOMY WITH RETROSTERNAL GASTRIC TUBE RECONSTRUCTION3
Magnetic sphincter augmentation: considerations for use in Barrett’s esophagus3
149. DOES PSEUDO-LYMPH NODE SKIP METASTASIS AFTER NEOADJUVANT THERAPY AFFECT ESOPHAGEAL SQUAMOUS CELL CARCINOMA OUTCOMES?—A MULTICENTER STUDY3
474. MANOMETRIC IDENTIKIT OF A FUNCTIONING AND EFFECTIVE FUNDOPLICATION IN THE HIGH-RESOLUTION MANOMETRY ERA3
289. RISK FACTOR OF RELAPSE IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA WHO ACHIEVE PATHOLOGIC COMPLETE RESPONSE TO NEOADJUVANT CHEMORADIOTHERAPY3
Is systematic formal crural repair mandatory at the time of magnetic sphincter augmentation implantation?3
Pre-treatment differential correlation of gene expression and response to topical steroids in eosinophilic esophagitis3
The risk of autism spectrum disorder and intellectual disability but not attention deficit/hyperactivity disorder is increased in individuals with esophageal atresia3
296. A BEGINNER’S THREE-YEAR LEARNING CURVE WITH ESOPHAGECTOMIES: A STUDY FROM A PERIPHERAL CANCER CENTRE IN NORTH-EAST INDIA3
456. THE USEFULNESS OF NEOADJUVANT CHEMOTHERAPY FOR SIEWERT TYPE II EGJ ADENOCARCINOMA3
368. THE ROLE OF PG-SGA SCORE IN PREDICTING SHORT- TERM POSTOPERATIVE COMPLICATIONS IN ESOPHAGEAL CANCER SURGERY2
134. MEDIASTINOSCOPIC ESOPHAGECTOMY AS A VIABLE APPROACH FOR ESOPHAGEAL PERFORATION: A 10-CASE REVIEW2
166. ROBOTIC-ASSISTED BILATERAL EPIPHRENIC DIVERTICULECTOMY WITH HELLER MYOTOMY AND DOR FUNDOPLICATION: A SURGICAL TECHNIQUE2
448. EFFECTS OF DIFFERENT ANALGESIC MODALITIES ON PAIN RELIEF AND SAFETY AFTER MINIMALLY INVASIVE ESOPHAGECTOMY: A RANDOMIZED CONTROLLED CLINICAL STUDY2
Contributing factors to lymph node recovery with esophagectomy by thoracic surgeons: an analysis of the Society of Thoracic Surgeons General Thoracic Surgery Database2
737. ETHNIC, GENDER AND TUMOR-SPECIFIC ASSESSMENT OF BODY COMPOSITION IS CRITICAL FOR CLINICAL RELEVANCE IN PATIENTS UNDERGOING THERAPY FOR ESOPHAGEAL2
430. PROGNOSTIC PATTERNS OF LYMPH NODES WITH COMPLETE TREATMENT RESPONSE IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA AFTER NEOADJUVANT CHEMORADIOTHERAPY AND NEOADJUVANT CHEMOTHERAPY2
Sex differences in survival following surgery for esophageal cancer: A systematic review and meta-analysis2
Single-center experience in implementation of endoscopic surveillance protocol after esophagectomy2
011. OUR SURGICAL TECHNIQUE OF COMBINED RESECTION WITH AORTIC ADVENTITIA USING DA VINCI XI FOR ESOPHAGEAL CANCER INVADING DESCENDING AORTA2
414. ILEOCOLON GRAFT VS GASTRIC CONDUIT IN ESOPHAGEAL RECONSTRUCTION FOR ESOPHAGEAL CANCER: ENHANCED QUALITY OF LIFE WITH COMPARABLE SURVIVAL OUTCOMES2
248. PLEURAL MONITORING FOR ANASTOMOTIC LEAKAGE AFTER TRANSTHORACIC ESOPHAGECTOMY FOR CANCER WITH LACTATE, LACTATE DEHYDROGENASE, AMYLASE, AND GLUCOSE2
202. THE INFLUENCE OF SOCIOECONOMIC DISADVANTAGE ON SHORT- AND LONG-TERM OUTCOMES AFTER OESOPHAGECTOMY FOR CANCER: AN AUSTRALIAN MULTICENTRE STUDY2
453. THE EFFECTIVITY OF NEOADJUVANT CHEMORADIOTHERAPY IN ESOPHAGEAL ADENOCARCINOMA WITH PRESENCE OF EXTRACELLULAR MUCINE, SIGNET-RING CELLS OR POORLY COHESIVE CELLS2
484. OESOPHAGECTOMY FOR CANCER: BEARING ON PATIENTS’ CHOICES2
537. ASSESSING THE EFFECT OF HIATAL HERNIA SIZE ON PERIOPERATIVE OUTCOMES AND HOSPITAL READMISSION RATES AFTER PRIMARY REPAIR2
263. CLINICAL PRESENTATION, DIAGNOSIS AND MANAGEMENT OF EARLY, AVERAGE AND LATE ONSET ANASTOMOTIC LEAKAGE AFTER ESOPHAGECTOMY2
344. SURGICAL APPROACH FOR SPONTANEOUS ESOPHAGEAL RUPTURE: THORACOSCOPY COMBINED WITH GASTROSCOPY AND TRADITIONAL THORACOTOMY2
335. LONG TERM RISK FOR PROGRESSION TO NEOPLASIA FOR BARRETT’S ESOPHAGUS PATIENTS WITH VALIDATED LOW-GRADE DYSPLASIA OR INDEFINITE FOR DYSPLASIA2
807. A REVISED APPROACH TO THE ESOPHAGOGASTRIC JUNCTION: A MODIFIED SIEWERT CLASSIFICATION2
227. CAUSES OF IN-HOSPITAL MORTALITY FOLLOWING TRANSTHORACIC ESOPHAGECTOMY FOR CANCER2
115. EVALUATING BODY MASS INDEX IN SURVIVAL AND COMPLICATIONS OF OLDER OESOPHAGEAL SQUAMOUS CELL CARCINOMA AFTER ESOPHAGECTOMY: A PROPENSITY SCORE ANALYSIS2
087. LAPAROSCOPIC MEDIASTINAL APPROACH TO TOTAL GASTRIC TUBE RESECTION FOR GASTRIC TUBE CANCER THROUGH A RETROSTERNAL ROUTE2
364. IMPROVING PRE-OPERATIVE EMOTIONAL DISTRESS SHORTENS HOSPITALIZATION FOR ESOPHAGECTOMY2
212. MANAGEMENT OF CT2N0M0 ESOPHAGEAL CANCER: A PROTOCOL FOR SYSTEMATIC REVIEW AND CLINICAL PRACTICE GUIDELINES2
138. MULTI-CENTER CLINICAL ANALYSIS AND SINGLE-CELL SEQUENCING INSIGHTS INTO THE DEVELOPMENTAL MECHANISMS OF SYNCHRONOUS MULTIPLE PRIMARY ESOPHAGEAL SQUAMOUS CELL CARCINOMA2
244. A NOVEL SERUM GLYCOPROTEIN BIOMARKER PANEL FOR SCREENING OF ESOPHAGEAL ADENOCARCINOMA AND SURVEILLANCE OF BARRETT’S ESOPHAGUS2
460. INITIAL EXPERIENCE OF MINIMALLY INVASIVE ESOPHAGECTOMY FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA AS A GASTROINTESTINAL SURGEON2
509. DOES SARCOPENIA AFFECT THE OUTCOME OF PATIENTS WITH ESOPHAGEAL CARCINOMA AFTER ESOPHAGECTOMY?2
International Society for Diseases of the Esophagus consensus on management of the failed fundoplication2
167. LYMPHATIC INVASION CAN PREDICT POSTOPERATIVE LYMPH NODE RECURRENCE IN PATIENTS WITH ESOPHAGEAL SQUAMOUS CELL CARCINOMA2
286. TREATMENT WITH CURATIVE INTENT FOR OLIGOMETASTATIC GASTROESOPHAGEAL CANCER-RESULTS OF A PROSPECTIVE MULTICENTER STUDY2
552. LAPAROSCOPIC RE DO FUNDOPLICATION2
227. RELATIONSHIP BETWEEN 90-DAY PROGNOSIS NUTRITIONAL INDEX AND INFLAMMATORY RESPONSE MARKERS AND LONG-TERM SURVIVAL IN ESOPHAGEAL CANCER2
645. CLINICAL SIGNIFICANCE OF LOCAL TREATMENT FOR RECURRENCE WITHIN THE SURGICAL FIELD AFTER RADICAL ESOPHAGECTOMY2
343. TEXTBOOK OUTCOMES OF ESOPHAGECTOMIES FROM A LOW VOLUME CANCER CENTRE IN INDIA2
479. MINIMALLY INVASIVE OESOPHAGECTOMY VS. OPEN: SHORT-TERM RESULTS2
385. TRANSLATING MOLECULAR-TARGETING FLUORESCENT PROBES IN OESOPHAGEAL CANCER PRE-CLINICAL MODELS1
623. A NEW PROGNOSTIC EVALUATION OF POSTOPERATIVE ESOPHAGEAL CANCER: LONG-TERM FLAIL INVESTIGATION1
081. IMPACT OF GASTRIC TUBULIZATION IN MCKEOWN ESOPHAGECTOMY ON PATIENT-REPORTED OUTCOMES1
282. PROGNOSTIC FACTORS IN ESOPHAGEAL MELANOMA: A SYSTEMATIC REVIEW AND ANALYSIS1
TikTok and Bilibili as health information sources on gastroesophageal reflux disease: an assessment of content and its quality1
366. SURGERY VERSUS NON-SURGICAL TREATMENT FOR THORACIC ESOPHAGEAL CANCER IN PATIENTS OLDER THAN 70 YEARS: A RETROSPECTIVE ANALYSIS OF 749 CASES1
Outcomes of repeated endoscopic submucosal dissection for superficial Esophageal squamous cell carcinoma on endoscopic resection scar1
494. GIANT GASTROINTESTINAL STROMAL TUMOR OF THE ESOPHAGUS: REPORT OF TWO CASES1
416. BIOMARKER IDENTIFICATION FOR CHEMOTHERAPY RESPONSE PREDICTION IN BARRETT’S CARCINOMA PATIENTS BY AN INFLAMMATORY-RELATED PLASMA PROTEIN PROFILING1
330. PRE-EMPTIVE ENDOLUMINAL VACUUM THERAPY WITH A SURGICAL DRAIN FOR REDUCTION OF ANASTOMOTIC LEAK RATE FOLLOWING MINIMALLY INVASIVE ESOPHAGECTOMY1
323. CLINICAL CHARACTERISTICS OF HIATAL HERNIA WITH ANEMIA AND SIGNIFICANCE OF SURGICAL REPAIR1
564. PRONE POSITION THORACOSCOPIC HAND-SEWN ESOPHAGO-GASTRIC ANASTOMOSIS DURING 2-STAGE TOTALLY MINIMALLY INVASIVE ESOPHAGECTOMY FOR CANCER. SURGICAL TECHNIQUE1
539. ASSOCIATION BETWEEN WAITING PERIOD FOR RADICAL SURGERY AND POSTOPERATIVE RELAPSE IN CLINICAL STAGE I ESOPHAGEAL CANCER1
254. QUANTIFYING PERIOPERATIVE RISKS FOR ANTIREFLUX AND HIATUS HERNIA SURGERY: A MULTICENTER COHORT STUDY OF 4301 PATIENTS1
154. EVALUATION OF BLOOD FLOW IN RECONSTRUCTED GASTRIC TUBE AND IDENTIFICATION OF OPTIMAL ANASTOMOSES IN ESOPHAGECTOMY1
288. COMPARISON OF LAPAROSCOPIC SURGERIES WITH OR WITHOUT HAND-ASSISTED PROCEDURE IN THE ABDOMINAL PHASE OF THORACOSCOPIC ESOPHAGECTOMY:A PROPENSITY SCORE-MATCHED STUDY1
Laparoscopic ischemic conditioning prior esophagectomy in selected patients: the ISCON trial1
424. EFFECT OF GUT MICROBIOTA ON THE RESPONSE TO NEOADJUVANT IMMUNOTHERAPY COMBINED WITH CHEMOTHERAPY IN PATIENTS WITH ESOPHAGEAL SQUAMOUS CELL CARCINOMA1
450. TISSUE RESIDENT MEMORY CELLS: CORRELATING THE PHENOTYPIC AND FUNCTIONAL CAPABILITIES OF A POTENTIAL TUMOUR REACTIVE CELL POPULATION IN OESOPHAGEAL ADENOCARCINOMA1
794. RETROSPECTIVE ANALYSIS OF CLINICAL CHARACTERISTICS AND PROGNOSIS OF SYNCHRONOUS MULTIPLE PRIMARY ESOPHAGEAL SQUAMOUS CELL CARCINOMA1
290. EVALUATION OF THE POST-OPERATIVE GERD AND RESIDUAL CHEST PAIN AFTER POEM1
334. DEFINITION OF SEVERE BENIGN OESOPHAGEAL STRICTURES AND IDENTIFICATION OF ASSOCIATED RISK FACTORS1
144. OPTIMIZING MEDIASTINAL ACCESS FOR RADICAL ESOPHAGECTOMY: A BILATERAL CERVICAL AND TRANSHIATAL APPROACH TO RESECT ESOPHAGEAL CANCER1
Botulinum toxin injection of the lower esophageal sphincter to identify achalasia-variant esophagogastric junction outflow obstruction1
195. POSTOPERATIVE DISTANT RECURRENCE PATTERN FOR RESECTABLE ESOPHAGEAL CANCER TREATED WITH NEOADJUVANT THERAPY: A SYSTEMATIC REVIEW AND META-ANALYSIS1
511. IS IT SAFE TO USE NONABSORBABLE MESH IMPLANTATION FOR HIATAL REINFORCEMENT DURING PRIMARY ANTIREFLUX PROCEDURES?1
18. REFLUX OF DUODENAL CONTENTS INDUCES ESOPHAGEAL CARCINOGENESIS (SCC, ADC)1
410. ROBOTIC-ASSISTED REPAIR OF A GIANT PARA-ESOPHAGEAL HERNIA1
350. THE ‘TIMING PARADOX’ OF ESOPHAGEAL CARCINOMA SURVEILLANCE: FAVORABLE BIOLOGY REQUIRES LONGER FOLLOW-UP1
Impact of staging investigations on nodal upstaging in early esophago-gastric adenocarcinoma: multicenter CONGRESS dataset analysis1
377. NEOADJUVANT CARBOPLATIN/PACLITAXEL VERSUS 5-FLUOROURACIL/CISPLATIN IN COMBINATION WITH RADIOTHERAPY FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A MULTICENTER COMPARATIVE STUDY1
785. MANAGEMENT OF ESOPHAGEAL CANCER WITH CONCURRENT CERVICAL NODE METASTASIS: A NATIONWIDE POPULATION-BASED COHORT STUDY1
421. THE STAPLED ANASTOMOSIS IN ESOPHAGECTOMY: NO DIFFERENCES IN LEAKAGE AND STRICTURE-RATES BETWEEN THE 25 MM AND 28 MM CIRCULAR STAPLER1
624. LONG-TERM OUTCOME OF NEOADJUVANT CHEMOTHERAPY FOLLOWED BY ESOPHAGECTOMY VERSUS DEFINITIVE PROTON BEAM THERAPY FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA1
766. LASTING SYMPTOMS AFTER OESOPHAGEAL RESECTIONAL SURGERY (LASORS): MULTICENTRE VALIDATION COHORT STUDY1
Cytosponge procedures produce fewer respiratory aerosols and droplets than esophagogastroduodenoscopies1
Complete pathologic response in esophageal adenocarcinoma: does it make a difference?1
0.13723993301392